Mitomycin C (MMC) is used for hyperthermic intraperitoneal chemotherapy (HIPEC) that, combined with cytoreductive surgery (CRS), comprises the treatment of patients with peritoneal metastases (PMs) originating from colorectal carcinoma (CRC) ([@bib8]). Because of the characteristics of PMs, CRS will leave microscopic disease *in situ*, hence requiring HIPEC with MMC ([@bib16]; [@bib9]). Mitomycin C is the drug of choice because of the direct cytotoxicity and the penetrance of only 1 to 2 mm ([@bib6]; [@bib45]). This is thought to cause minimal systemic side effects, while still eliminating minimal residual disease after CRS ([@bib46]). A randomised clinical trial (RCT) in 2003 showed an median overall survival of 22.4 months in patients treated with HIPEC with MMC *vs* 12.6 months in patients treated with systemic chemotherapy alone ([@bib47]). Several other clinical trials followed, revealing a comparable survival gain, with one trial even showing a median overall survival of 62 months ([@bib20]; [@bib5]; [@bib14]). Even when patients are stratified according to the extent of metastasis and residual disease after resection, a subset of patients have decreased survival, giving rise to our hypothesis that these patients might respond differently to MMC ([@bib20]; [@bib47]). If identified, these patients could benefit from an altered approach with optimised tailored treatment with alternative drugs that are readily available and clinically applicable in the HIPEC setting, such as oxaliplatin, irinotecan and doxorubicin ([@bib25]; [@bib45]; [@bib8]).

Mitomycin C functions by intercalating or crosslinking DNA and creating DNA damage, disrupting DNA replication, heralding mitosis and ultimately leading to apoptosis ([@bib43]). The cancer cell has several ways of evading and/or repairing MMC-induced damage. One possible way is to inhibit MMC activation as MMC requires enzymatic reduction to become active ([@bib11]). Several reductases have this capacity, with DT-diaphorase being the most potent and widely researched ([@bib43]; [@bib36]; [@bib19]; [@bib30]). Absence of this enzyme has been known to lead to increased resistance to MMC in cancer cells ([@bib19]). Another way for cancer cells to overcome MMC-induced damage is to repair this damage. This can be facilitated by either the Fanconi anaemia--BRCA (FA--BRCA) pathway or the ATM--ATR pathway that, in turn, both regulate the RAD51C nuclear foci to mediate repair by homologous recombination or nucleotide excision repair ([Figure 1](#fig1){ref-type="fig"}) ([@bib12]; [@bib44]). Theoretically, if either of these pathways remain intact or even hyperactivated, MMC-related DNA damage could be partially repaired and some degree of resistance can be expected, whereas a nonfunctional pathway may lead to MMC sensitivity as seen in lymphoblasts derived from FA patients ([@bib1]; [@bib33]). A similar principle has been exposed before in non-small-cell lung carcinoma, where the knockout of the FA--BRCA pathway led to a three- to five-fold increase in sensitivity to cisplatin, bearing some resemblance to MMC ([@bib18]).

With a mortality ranging from 3% to 5% and a morbidity ranging from 15% to 50%, it is necessary to select patients who will benefit maximally from CRS with HIPEC and exclude patients whose survival gain does not outweigh the treatment-associated morbidity and mortality ([@bib37]; [@bib5]; [@bib4]; [@bib31]). However, no predictive biomarkers have been found to date that complement the clinical characteristics known to predict outcome ([@bib15]). The aim of this study is to characterise biomarkers that predict treatment response to MMC in patients receiving HIPEC for PMs of CRC in order to tailor treatment and subsequently improve survival post CRS and HIPEC.

Materials and methods
=====================

Cell lines and drug sensitivity
-------------------------------

Twelve CRC cell lines, HCT116, HCT15, Colo205, Colo320, SW480, SW48, SW1398, CaCo-2, HT-29, LS174T, RKO and LIM1863, were kindly provided by the Tumor Profiling Unit of the Department of Pathology of VU University Medical Center. All cell lines, except LIM1863, were obtained from American Type Culture Collection (LGC Standards GmbH, Wesel, Germany). LIM1863 was kindly provided by Dr RH Whitehead from the Ludwig Institute for Cancer Ltd (Melbourne branch) ([@bib49]). The cell lines were routinely authenticated on the basis of aCGH copy number profile, viability, growth rate and morphology by microscopic examination.

Drug sensitivity of cell lines was determined by the SRB assay ([@bib2]). The IC~50~ values were extracted from the produced graphs. Experiments were conducted in triplicate and the mean of the three experiments is shown.

In order to assess FA--BRCA pathway functionality, negative and positive controls VU1131-T2-8 and VU1131-T2-8 +FANCC cell lines were taken along in the analysis. We categorised cell lines as sensitive, intermediate and resistant in comparison with control cell lines.

Expression array
----------------

The RNA was isolated of all 12 CRC cell lines (Ambion Inc., Austin, TX, USA). Synthesis and cDNA labelling were performed according to the manufacturer\'s recommendations including QC (Agilent Technologies, Palo Alto, CA, USA). Hybridisation was performed on single 44K formatted expression arrays containing 41 675 60-mer oligonucleotides representing over 27 000 well-characterised full-length or partial human genes and expressed sequence tag clusters (G4112A, Agilent Technologies). Scanning was performed using a microarray scanner G2505B (Agilent Technologies) and Feature Extraction v9.5 using the manufacturers protocols (Agilent Technologies). LIMMA-package was used for of background correction, loss within array normalisation and quantile between-array normalisation ([@bib41]). A total of 37 genes and their mRNA products related to the FA--BRCA pathway, ATM--ATR pathway and/or enzymatic MMC activation were selected based on literature and pathway analysis ([@bib19]; [@bib11]; [@bib12]; [@bib44]; [@bib7]; [@bib23]) and subsequently correlated to MMC sensitivity. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE50494 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50494>).

FA--BRCA pathway status: chromosomal breakage assay and western blot
--------------------------------------------------------------------

The functionality of FA--BRCA pathway was tested with a chromosomal breakage assay ([@bib33]). Instead of venous blood described in the above-mentioned protocol, trypsinised cell cultures were used. Four slides were prepared per cell line, with MMC addition and without MMC. Metaphases were analysed using MetaphaseFinder (Applied Spectral Imaging Inc, Carlsbad, CA, USA) and scored by an experienced technician.

Fanconi anaemia complementation group D2 protein (FANCD2) was analysed by western blotting in MMC-sensitive cell lines ([@bib18]). Western blot was performed using an FANCD2 mouse antibody (F17, Santa Cruz biotechnology Inc., Heidelberg, Germany) diluted at 1 : 500 in 2% dry milk in TBST and a peroxidase-conjugated anti-mouse immunoglobulin diluted at 1 : 5000 in 2% dry milk in TBST. Cells were treated with hydroxyurea to determine FA pathway activation by monoubiquitination of FANCD2 in response to DNA damage.

Immunohistochemistry
--------------------

Immunohistochemistry was performed on 4 *μ*m slides from FFPE blocks containing embedded CRC cell lines. Slides were stained using the HIER pH6 protocol as described by the manufacturer. Rabbit anti-BLM antibody (Sigma-Aldrich Co. LLC, St Louis, MO, USA), obtained via the Human Protein Atlas (HPA), was utilised in dilution of 1 : 200 and subsequently incubated for 1 h at room temperature. This antibody has been validated in previous research ([@bib27]). Secondary antibody PowerVision Poly-HRP anti-Rabbit/Mouse/Rat antibody (Leica Biosystems BV, Nussloch, Germany) was used. Scoring was performed with simple light microscopy and scored by two independent microscopists. As described by HPA, normal liver tissue was used as negative control and placental tissue as positive control.

Patient material
----------------

All consecutive patients from a prospectively collected cohort in 2007--2010 undergoing CRS and HIPEC in an expert HIPEC centre (Catharina Hospital, Eindhoven, The Netherlands) with standardised treatment were investigated for Bloom syndrome protein (BLM) expression (*n*=33). Only patients with histologically confirmed diagnosis of PM of CRC were included. Tumour samples with \<70% tumour tissue were excluded after staining. Immunohistochemistry was performed with the same protocol as described above. Patient data were subsequently stratified by resection outcome and only R1 outcome, microscopic minimal residual disease ([@bib47]), was included in survival analysis (*n*=20). Median follow-up was 35.3 months with a minimum of 24 months and a maximum of 64 months. Collection, storage and use of tissue and patient data were performed in accordance with the Code for Proper Secondary Use of Human Tissue in the Netherlands.

Statistical analysis
--------------------

SPSS (version 17; IBM Corporation, Armonk, NY, USA) was used to analyse results. We used linear regression to find a correlation between expression data and clustered sensitivity data. Correlation between clustered sensitivity and immunohistochemistry was assessed using the *χ*^2^ test. Patient survival was analysed according to the Kaplan--Meier method. For all mentioned tests, a *P-*value of \<0.05 was considered significant.

Results
=======

MMC sensitivity
---------------

The IC~50~ for each cell line was clustered into sensitive (0--50 n[M]{.smallcaps}; *n*=1), intermediate (50--200 n[M]{.smallcaps}; *n*=7) and resistant (\>200 n[M]{.smallcaps}; *n*=4). Doubling time and MSS/MSI status did not correlate to sensitivity.

mRNA expression
---------------

The mRNA expression of 37 genes related to the FA--BRCA, ATM--ATR and MMC activation pathways were analysed for a correlation with clustered sensitivity ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). *BLM* demonstrated a significant correlation with sensitivity at mRNA level (*P*=0.01) as well as *BRCA2* (*P*=0.02). Both *BLM* and *BRCA2* were observed to be upregulated in the resistant cell lines ([Figure 2](#fig2){ref-type="fig"}). The expression of *FANCD2*, as key protein in the FA--BRCA pathway, displayed no significant correlation with clustered sensitivity. None of the genes of the ATM--ATR pathway or any of the activation enzymes exhibited any correlation to clustered MMC sensitivity (see [Supplementary Data](#sup1){ref-type="supplementary-material"}). Combined expression levels of *BLM* and *BRCA2* demonstrated no better correlation (*P*=0.01) than *BLM* alone. Multivariate analysis was not possible because of limited sample size.

FA--BRCA functionality
----------------------

Representative cell lines of each sensitivity cluster (sensitive: SW48; intermediate: SW1398 and LS174T; resistant: HCT15) were selected for chromosomal breakage assay. Over 90% of positive control cells (VU1131-T2-8) displayed \>10 breaks per cell, consistent with a nonfunctional FA--BRCA pathway. Over 80% of negative control cells (VU1131-T2-8+FANCC) showed less than three breaks per cells. SW48, HCT15 and LS174T were comparable with the negative control (over 80% of cells with less than three breaks) ([Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). SW1398 exhibited slightly more breaks, yet demonstrated in over 80% of the cells less than five breaks and was considered negative for chromosomal breakage.

Sensitive cell line SW48 expressed a FANCD2 band on western blot, indicating the presence of the FANCD2 protein, as well as a darker second band with slower mobility after 24 h of hydroxyurea treatment, illustrating that FANCD2 could be monoubiquitinated and thus be activated ([Supplementary Figure 1B](#sup1){ref-type="supplementary-material"}).

Immunohistochemistry on BLM
---------------------------

Immunohistochemical staining revealed nuclear and less intense cytoplasmatic staining with significant intratumour heterogeneity, in concordance with previous studies ([@bib42]). Considering the nuclear propensity of active BLM and the most active part of the tumour dictating the ultimate response, the strongest nuclear component of staining was scored and used for analysis. Intensity was scored as negative, weak, moderate or strong ([Figure 3](#fig3){ref-type="fig"}). Interobserver variability was \<5%. We observed no correlation between mRNA and staining intensity. Correlation between clustered sensitivity and separate staining intensity was not significant (*P*=0.17). However, negative and weak intensity *vs* moderate and strong intensity was significantly associated with high *vs* low sensitivity (*P*=0.04).

In patient material, 20 out of 33 patient samples were selected by R1 resection outcome. Six patient samples were scored with low intensity (negative plus weak) and 14 patient samples with high intensity (moderate plus strong) for BLM protein ([Figure 4](#fig4){ref-type="fig"}). Median survival for R1 patients was 23 months (95% CI: 11.5--34.5). A significant longer survival was found in favour of low BLM expression (high: 15 months (11.3--18.7) *vs* low: NR; *P*=0.04; [Figure 5](#fig5){ref-type="fig"}).

Discussion
==========

In this study, we demonstrate an association of low BLM with a high sensitivity to MMC and an improved survival. Considering BLM is linked to the FA--BRCA pathway, which is known to play a role in MMC sensitivity, this association seems not unexpected.

In order to select a potential biomarker, we investigated expression levels of 37 different genes involved in the FA--BRCA, ATM--ATR and MMC activation pathways, together responsible for both the activation of MMC and repairing MMC-induced damage, in association to the MMC sensitivity in 12 CRC cell lines. A significantly higher mRNA expression of both *BRCA2* and *BLM* were found in cell lines resistant to MMC. We found that sensitivity to MMC not only associates to *BLM* on mRNA level, but also to BLM on protein level. Immunohistochemical analysis of BLM protein correlated to MMC sensitivity in our 12 CRC cell lines. Furthermore, in a prospectively collected cohort of patients with minimal residual disease after CRS, treated with HIPEC using MMC, BLM protein expression was associated with a decreased overall survival.

We linked MMC sensitivity to *BLM* and *BRCA2*, strongly suggesting a role for the FA--BRCA pathway in the development of chemoresistance in CRC, yet the chromosomal breakage assay demonstrated no dysfunction of the FA--BRCA pathway in CRC cell lines of any MMC sensitivity level. Concordantly, we observed no association to FANCD2 mRNA or protein expression. This leads to the conclusion that although BLM correlates with MMC sensitivity, this seems to have no implications for the function of DNA repair of the FA--BRCA pathway. It appears that the FA--BRCA pathway can function with either decreased expression levels or is of only limited importance in the development of resistance to MMC in CRC. Hypothetically, the FA--BRCA pathway itself may not be involved in the mechanism dictating response to MMC, but the molecules involved could rather represent surrogate markers for another, still unidentified, pathway that interacts with both BRCA2 and BLM. Perhaps the increased genomic instability as mediated by low levels of BRCA2 and BLM leads to increased sensitivity to DNA crosslinking agents such as MMC. The discrepancies between mRNA and IHC that we found in two cell lines could be because of post-translational modifications. This complex process, consisting of several interacting proteins, is known to mediate protein expression and often relays mRNA expression in different levels of protein expression ([@bib21]).

Sensitivity to MMC is known to be correlated to DT-diaphorase, encoded by the *NQO1* gene ([@bib19]; [@bib39]; [@bib30]), yet the DT-diaphorase overexpressing cell line HT-29 is only intermediately sensitive in our cohort and none of the mRNA products of the MMC activation pathway were significantly correlated to MMC sensitivity. Activation of MMC by DT-diaphorase might be of inferior importance in sensitivity in CRC cell lines, perhaps because of the abundance of other MMC-activating enzymes in human cells that readily transform MMC to its active metabolite ([@bib11]; [@bib34]).

The BLM itself is a RecQ helicase that is primarily responsible for unwinding DNA and is known to participate in the BASC complex with BRCA1, the MRN complex (containing RAD50, MRE11 and NBS1) and interact directly with FANCD2 ([@bib17]; [@bib22]; [@bib48]; [@bib32]). On a cellular level, BLM is involved in stalled replication fork repair, homologous repair, non-homologous end joining and nucleotide excision repair ([@bib3]; [@bib38]; [@bib13]; [@bib35]). In contrast to several other DNA repair genes, that is *BRCA2*, the clinical implications of altered BLM expression have not been as well established in cancer ([@bib50]; [@bib10]; [@bib28]; [@bib40]). Even though clinical data are scarce, an important characteristic of BLM is its required activation for repair of DNA double-strand breaks, inducible by intercalating agents such as MMC ([@bib26]). Accordingly, a knockdown of BLM in cell lines sensitises these cells to cisplatin and camptothecin, indicating again the importance of BLM in chemotherapeutic response and its possible clinical relevance ([@bib29]).

In order to further characterise the role of BLM, RNA knockdown experiments in association with investigation of DNA repair proteins could be the next step. Another approach includes proteomics specifically targeting low-abundance nuclear proteins in order to determine the role of BLM in the development of resistance to crosslinking agents such as MMC in CRC cell lines. The results generated by proteomics should then subsequently be validated in a well-defined CRS and HIPEC cohort from an expert HIPEC centre. The ultimate clinical goal is to be able to differentiate between responders and nonresponders to MMC. Nonresponders could then be treated with an alternative intraperitoneal compound.

We conclude that MMC sensitivity in CRC is associated with BLM expression. We are the first to have found a possible predictive biomarker for PMs of CRC and suggest further validation of BLM as a biomarker for treatment stratification before CRS and HIPEC.

We thank Kees Smid, Ietje Kathmann, Asma Esidahi and Anneke Oostra for their excellent technical support. In addition, we thank Meike de Wit and George Scheffer for their expert advice and critical appraisal of the immunohistochemical data. Furthermore, we would sincerely like to thank Dr Victor Verwaal (Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital) for his essential guidance and advice in the implementation of the CRS and HIPEC technique in our institute (2010) and thus enabling us to study this population of metastatic colorectal cancer patients.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![**Activation of MMC and repair mechanisms of double-strand breaks.** Both the FA--BRCA pathway and the ATM--ATR pathway are illustrated in summary. The FA--BRCA and ATM--ATR pathways have common proteins and intersect on several levels ([@bib11]; [@bib24]; [@bib7]; [@bib23]).](bjc201518f1){#fig1}

![**The *BLM* and *BRCA2* expression correlated to sensitivity to MMC.** Resistant cell lines show higher levels of *BLM* expression (*P*=0.01) and higher levels of *BRCA2* expression (*P*=0.02).](bjc201518f2){#fig2}

![**Immunohistochemistry on BLM.** (**A--C**) Blank, negative (liver) and positive (placenta) controls respectively at × 10 objective magnification. (**D**) SW48 with weak staining ( × 20 objective magnification). (**E**) HT29 with moderate staining ( × 20 objective magnification). (**F**) Strong staining on Colo205 ( × 20 objective magnification).](bjc201518f3){#fig3}

![**Immunohistochemistry on patient material for BLM.** From left to right: negative, weak, moderate and strong intensity staining ( × 20 objective magnification). Negative and weak were clustered for analysis into 'low\' as well as moderate and strong into 'high\'. Low *vs* high was significantly correlated to survival (*P*=0.04).](bjc201518f4){#fig4}

![**Kaplan--Meier curve of patients with a R1 resection outcome.** Patients with a low BLM protein expression demonstrate significant better survival than patients with a high BLM protein expression (*P*=0.04).](bjc201518f5){#fig5}
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